Antibody levels increase significantly after the 3rd vaccination – in people with healthy immune systems and cancer patients.
Since 2020, the Coronavirus SARS-CoV-2 has kept the world on tenterhooks, and only recently, the end of Corona protective measures could be decided and announced. The reason for this is stable immunity within the population – on the one hand, through infections that have been passed through, and on the other hand, through the protective vaccination.
Three Corona vaccinations are needed for basic immunization, and to refresh protection, a fourth sting is now recommended for all persons 12 years of age and older.
A recent study by the Karl Landsteiner Private University for Health Sciences confirms the third vaccination’s importance. In particular, those affected by B-cell cancers would benefit from the 3rd sting. It would then, even if the 2nd vaccination had not yet shown any effect, antibodies would finally be formed.
For people with cancers of cells essential to the immune system, the Corona vaccination was often sobering because there was hardly any immune response, so hardly any antibodies were formed. The new study from the University of Lower Austria now proves that the 3rd prick brings a turnaround and lets the production of antibodies pick up speed.
And even in healthy people, according to results from Karl Landsteiner Private University, antibody levels rise significantly after the 3rd vaccination, according to a news release. The study provides important insights for future vaccination strategies, especially among vulnerable groups.
“Our results clearly show the importance of a third vaccination as the completion of basic immunization for affected cancer patients,” explains study leader Dr. Josef Singer (Clinical Department of Internal Medicine 2 of the University Hospital Krems, teaching and research site (KL Krems).
“Because in fact, even after the second vaccination, we were unable to detect the production of antibodies against SARS-CoV-2 in half of our patients – whereas the third vaccination then did lead to an immune response in more than one-third of these individuals,” says the study leader.
Eighty patients from the University Hospital Krems cancer centers and the Medical University of Vienna were examined for the scientific study. Eight different B-cell-based cancers, including non-Hodgkin’s lymphoma, which was treated differently, were included in the samples. The study has now been published internationally.
- source: heute.at/picture: pixabay.com
This post has already been read 1040 times!